Many lipid-lowering therapies exist, such as statins to manage and reduce lipid levels. While statins are the most commonly used medication, some patients may need additional interventions to lower their LDL cholesterol levels. In this touchCARDIO interview, we speak with Prof. Steven Nissen (Cleveland Clinic, Cleveland, OH, USA) to explore current and developing novel lipid-lowering mechanisms to reduce cardiovascular risk.
The abstract entitled ‘Bempedoic Acid And Cardiovascular Outcomes In Statin Intolerant Patients At High Cardiovascular Risk‘ (Abstract number 402-06) was presented at ACC.23 Together With WCC (ACC.23/WCC) in New Orleans, 4–6 March 2023.
Dr Steven Nissen also discusses the CLEAR OUTCOMES trial results investigating bempedoic acid and cardiovascular outcomes in statin intolerant patients
Questions:
- Could you give us a brief overview of the lipid lowering treatment landscape, and what are the current treatment gaps? (0:15)
Disclosures: Dr. Nissen reports that the Cleveland Clinic Center for Clinical Research has received funding to perform clinical trials from Abbvie, AstraZeneca, Amgen, Bristol Myers Squibb,
Eli Lilly, Esperion, Medtronic, MyoKardia, New Amsterdam Pharmaceuticals, Novartis, Pfizer, and Silence Therapeutics. Dr. Nissen is involved in these clinical trials but receives no personal remuneration for his participation. Dr. Nissen consults for many pharmaceutical companies, but does not accept compensation.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of ACC 2023
Access more content on cardiovascular disease and lipid management
